Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 1, 2026Advanced Materials

Utilizing Rationally Designed Photosensitizers to Drive Divergent Immunogenic Cell Death in Photoimmunotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

JHJ HuangZWZi WangHLHui Li

Discussion

Loading...

Member takes

Overview

Randomized trial demonstrates immune response differences in type I and type II photodynamic therapy agents, suggesting a new design approach.

Key Points

  • This research aims to investigate whether type I and type II photodynamic therapy induce different immune responses during cancer treatment using rationally designed photosensitizers.
  • Developed A-D-A structured organic photosensitizers via rational donor–acceptor engineering.
  • Conducted mechanistic investigations to compare the immunogenic potential of type I and type II photosensitizers.
  • Evaluated the immune response triggered by caspase-1-mediated pyroptosis.
  • Type I photosensitizers are more effective than type II in triggering caspase-1-mediated pyroptosis.
  • Type I photosensitizers lead to stronger immune activation and release of pro-inflammatory factors.
  • Under low-power 808 nm photoirradiation, the leading type I agent induces a more robust systemic antitumor response.

Cite This Study

Huang et al. (2026) studied this question.

synapsesocial.com/papers/6a44af325cd2549c8bc443a1https://doi.org/10.1002/adma.202522822
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Type I/II Photosensitizer with Lysosome-Targeting Capabilities Induces Immunogenic Cell Death in Cancer Cells to Enhance Tumor Immunotherapy2026 · 11 citations
  2. 2Targeted Photoredox System under a Hypoxic Environment to Evoke Photodynamic Immunotherapy2025 · 8 citations
  3. 3Editorial: Combination of photodynamic therapy and immunotherapy to overcome cancer resistance2026 · 2 citations
  4. 4Harnessing Immunogenic PANoptosis With Iridium(III) Biradical Photosensitizers for Melanoma Photoimmunotherapy2026 · 1 citations
  5. 5Mechanisms of triggering antitumor immunity: from photodynamic effects to immunogenic cell death2024